These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 15584922

  • 1. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates.
    Bade S, Rummel A, Reisinger C, Karnath T, Ahnert-Hilger G, Bigalke H, Binz T.
    J Neurochem; 2004 Dec; 91(6):1461-72. PubMed ID: 15584922
    [Abstract] [Full Text] [Related]

  • 2. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.
    Baldwin MR, Bradshaw M, Johnson EA, Barbieri JT.
    Protein Expr Purif; 2004 Sep; 37(1):187-95. PubMed ID: 15294297
    [Abstract] [Full Text] [Related]

  • 3. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.
    Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, Lawrence GW, Dolly JO.
    FEBS J; 2012 Jul; 279(14):2555-67. PubMed ID: 22607388
    [Abstract] [Full Text] [Related]

  • 4. Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation.
    Ibañez C, Blanes-Mira C, Fernández-Ballester G, Planells-Cases R, Ferrer-Montiel A.
    FEBS Lett; 2004 Dec 03; 578(1-2):121-7. PubMed ID: 15581628
    [Abstract] [Full Text] [Related]

  • 5. Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain.
    Pirazzini M, Henke T, Rossetto O, Mahrhold S, Krez N, Rummel A, Montecucco C, Binz T.
    FEBS Lett; 2013 Nov 29; 587(23):3831-6. PubMed ID: 24157364
    [Abstract] [Full Text] [Related]

  • 6. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW, Chai Q, Christian T, Stevens RC.
    Biochemistry; 2006 Mar 14; 45(10):3255-62. PubMed ID: 16519520
    [Abstract] [Full Text] [Related]

  • 7. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
    Wang J, Zurawski TH, Meng J, Lawrence GW, Aoki KR, Wheeler L, Dolly JO.
    FASEB J; 2012 Dec 14; 26(12):5035-48. PubMed ID: 22942075
    [Abstract] [Full Text] [Related]

  • 8. Genetically engineered clostridial C2 toxin as a novel delivery system for living mammalian cells.
    Fahrer J, Plunien R, Binder U, Langer T, Seliger H, Barth H.
    Bioconjug Chem; 2010 Jan 14; 21(1):130-9. PubMed ID: 20030334
    [Abstract] [Full Text] [Related]

  • 9. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
    Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S, Aoki KR, Dolly JO.
    Biochem J; 2012 May 15; 444(1):59-67. PubMed ID: 22360156
    [Abstract] [Full Text] [Related]

  • 10. Recombinant expression and purification of the botulinum neurotoxin type A translocation domain.
    Lacy DB, Stevens RC.
    Protein Expr Purif; 1997 Nov 15; 11(2):195-200. PubMed ID: 9367816
    [Abstract] [Full Text] [Related]

  • 11. [Mechanisms of action of botulinum toxins and neurotoxins].
    Poulain B, Lonchamp E, Jover E, Popoff MR, Molgó J.
    Ann Dermatol Venereol; 2009 May 15; 136 Suppl 4():S73-6. PubMed ID: 19576489
    [Abstract] [Full Text] [Related]

  • 12. Cellular uptake of Clostridium botulinum C2 toxin: membrane translocation of a fusion toxin requires unfolding of its dihydrofolate reductase domain.
    Haug G, Wilde C, Leemhuis J, Meyer DK, Aktories K, Barth H.
    Biochemistry; 2003 Dec 30; 42(51):15284-91. PubMed ID: 14690438
    [Abstract] [Full Text] [Related]

  • 13. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.
    Koriazova LK, Montal M.
    Nat Struct Biol; 2003 Jan 30; 10(1):13-8. PubMed ID: 12459720
    [Abstract] [Full Text] [Related]

  • 14. Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A.
    Kadkhodayan S, Knapp MS, Schmidt JJ, Fabes SE, Rupp B, Balhorn R.
    Protein Expr Purif; 2000 Jun 30; 19(1):125-30. PubMed ID: 10833399
    [Abstract] [Full Text] [Related]

  • 15. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate.
    Fu Z, Chen S, Baldwin MR, Boldt GE, Crawford A, Janda KD, Barbieri JT, Kim JJ.
    Biochemistry; 2006 Jul 25; 45(29):8903-11. PubMed ID: 16846233
    [Abstract] [Full Text] [Related]

  • 16. Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons.
    O'Leary VB, Ovsepian SV, Raghunath A, Huo Q, Lawrence GW, Smith L, Dolly JO.
    Gene Ther; 2011 Jul 25; 18(7):656-65. PubMed ID: 21368902
    [Abstract] [Full Text] [Related]

  • 17. Differential entry of botulinum neurotoxin A into neuronal and intestinal cells.
    Couesnon A, Shimizu T, Popoff MR.
    Cell Microbiol; 2009 Feb 25; 11(2):289-308. PubMed ID: 19016790
    [Abstract] [Full Text] [Related]

  • 18. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ.
    Mol Immunol; 2007 Feb 25; 44(5):1029-41. PubMed ID: 16647121
    [Abstract] [Full Text] [Related]

  • 19. Delivery into cells: lessons learned from plant and bacterial toxins.
    Sandvig K, van Deurs B.
    Gene Ther; 2005 Jun 25; 12(11):865-72. PubMed ID: 15815697
    [Abstract] [Full Text] [Related]

  • 20. Adaptation of Clostridium difficile toxin A for use as a protein translocation system.
    Kern SM, Feig AL.
    Biochem Biophys Res Commun; 2011 Feb 25; 405(4):570-4. PubMed ID: 21266163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.